Novartis: beta-Thalassemia trials

The registry lists 11 beta-Thalassemia studies with Novartis as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 2 5Phase 3 3Phase 4 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2/3Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years OldWithdrawnNCT01724138Phase 4
• Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
• A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 3
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
• Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 3